Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

O2 Versus CPAP Treatment Of Patients Undergoing SIPE Therapy (OCTOPUS) (OCTOPUS)

30. september 2026 oppdatert av: Maria Hårdstedt, Dalarna County Council, Sweden

Evaluering av kontinuerlig positivt luftveistrykk (CPAP) i svømmeindusert lungeødem (SIPE) - en randomisert enkeltblindet kontrollert studie

In swimming induced pulmonary edema (SIPE), there is a lack of knowledge regarding optimal treatment. The present study was designed to assess the benefit of continuous positive airway pressure (CPAP) compared to oxygen as a first line treatment of SIPE in the out-of-hospital environment.

Studieoversikt

Detaljert beskrivelse

Swimming induced pulmonary edema (SIPE) is an unusual condition affecting otherwise healthy swimmers. SIPE is characterized by acute onset of dyspnea and cough, excessive sputum and occasionally hemoptysis when swimming in open water. The condition usually resolves spontaneously within 48 hours, but may result in serious illness and require emergency care. Case reports describe acute treatment with oxygen alone or in combination with diuretics, beta-agonist-inhalation or continuous positive airway pressure (CPAP). Evidence for optimal treatment strategy is lacking. This study intends to determine whether oxygen alone or applied together with CPAP leads to improvement of oxygen saturation and recovery of patients. The aim is to treat patients on site without involving hospital care. We study a large cohort of approximately 12 000 swimmers during Vansbrosimningen, Sweden's biggest annual open water event with a yearly incidence of SIPE about 0,4%.

Adult patients clinically diagnosed with SIPE are randomly assigned in 2 groups receiving treatment during 20 minutes: (1) oxygen 10l/min or (2) oxygen 10l/min and CPAP 7,5 cm H2O. Assessment with outcome measures is taken 10 minutes after treatment. Primary endpoint: oxygen saturation (%) by pulse oxymetry.

Studietype

Intervensjonell

Registrering (Antatt)

90

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Falun, Sverige, 79182
        • Rekruttering
        • Center of Clinical Research Dalarna

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • clinical diagnosis of swimming induced pulmonary edema (SIPE) with need of acute treatment (oxygen saturation ≤91%)
  • 18 years and older
  • informed consent

Exclusion Criteria:

  • declined consent
  • suspected acute coronary syndrome
  • severe asthma diagnosed together with pulmonary edema where beta-agonist-inhalation is needed prior to treatment of pulmonary edema
  • hemodynamic instability or decreased consciousness

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Oksygen + CPAP-behandling

Oxygen-driven CPAP (7,5 cmH2O): 20 min treatment followed by 10 min rest and assessment

Aktiv komparator: Oksygen-behandling

Oxygen: 20 min treatment followed by 10 min rest and assessment

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Absolute peripheral oxygen saturation (%) after treatment
Tidsramme: after 20 min treatment followed by 10 min rest

Peripheral oxygen saturation % (continuous variable) measured by peripheral pulse oximetry

after 20 min treatment followed by 10 min rest

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in absolute peripheral oxygen saturation (%) before and after treatment
Tidsramme: change before versus after 20 min treatment followed by 10 min rest

Change in peripheral oxygen saturation % (continuous variable) measured by pulse oximetry before and after treatment

change before versus after 20 min treatment followed by 10 min rest
Recovery (yes/no) after treatment
Tidsramme: after 20 min treatment followed by 10 min rest

Recovery, defined by "peripheral oxygen saturation >95% after treatment" or no recovery, defined by "peripheral oxygen saturation ≤95% after treatment"

after 20 min treatment followed by 10 min rest
Absolute number of regions presenting B-lines on lung ultrasound after treatment
Tidsramme: after 20 min treatment followed by 10 min rest

Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Assessment of the total number of positive regions.

after 20 min treatment followed by 10 min rest
Change in absolute number of regions presenting B-lines on lung ultrasound before and after treatment
Tidsramme: change before versus after 20 min treatment followed by 10 min rest

Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Assessment of the total number of positive regions. Change in absolute number of regions presenting B-lines on lung ultrasound before and after treatment

change before versus after 20 min treatment followed by 10 min rest
Interstitial syndrome assessed by lung ultrasound (yes/no) after treatment
Tidsramme: after 20 min treatment followed by 10 min rest

Four chest regions for both lungs are scanned by lung ultrasound; a positive region defined by the presence of three or more B-line artifacts. Bilateral or unilateral presence of two or more positive regions define positive interstitial syndrome.

after 20 min treatment followed by 10 min rest
Change in patient reported outcome measures before and after treatment
Tidsramme: change before versus after 20 min treatment followed by 10 min rest

Six different patient reported outcome measures assessed by numeric rating scale (NRS) 0-10: cough, sputum, air hunger, breathing effort, tightness in chest, anxiousness. The patients will assess symptoms prior to and after treatment.

change before versus after 20 min treatment followed by 10 min rest
Admission to hospital (yes/no)
Tidsramme: 2 hours

admission to hospital within or after a maximal treatment time of 40 minutes followed by 20 min rest.

2 hours
total treatment time
Tidsramme: 2 hours

total treatment time until oxygen saturation ≥96% is reached.

2 hours
subgroup analysis
Tidsramme: 1 hour

treatment outcome analysis in patients with different baseline oxygen saturation on admission

1 hour

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. juli 2022

Primær fullføring (Antatt)

15. juli 2027

Studiet fullført (Antatt)

15. juli 2027

Datoer for studieregistrering

Først innsendt

4. februar 2020

Først innsendt som oppfylte QC-kriteriene

11. mars 2020

Først lagt ut (Faktiske)

13. mars 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere